For a low-dose fluorinated pyrrolidine hydrochloride intended as an immediate-release oral tablet in the 1.0 mg to 5.0 mg unit strength range, direct compression is treated as the default only after forced degradation screening under ICH Q1A at 40 °C/75 % RH over 6 months shows total impurities below 0.5 % area by HPLC and the desfluoro degradant below 0.10 % area. The API is loaded at 2.0–6.0 % w/w. A representative 2.5 mg strength uses 64.0 % w/w spray-dried lactose monohydrate, 30.0 % w/w microcrystalline cellulose Type PH-102, 3.0 % w/w croscarmellose sodium, 1.0 % w/w colloidal silicon dioxide, and 0.5 % w/w sodium stearyl fumarate. When the fluorinated pyrrolidine substituent contains a free primary amine, lactose monohydrate is replaced wholly by pearlitol mannitol to eliminate Maillard-type browning observed in accelerated lots at 40 °C/75 % RH; this substitution requires main compression force to be raised by 1.0–1.5 kN. Before blending, the API lot is pre-dried in a vacuum tray dryer at 40 °C for not less than 4 h if Karl Fischer moisture exceeds 0.5 % water; direct compression is not started above 60 % RH ambient. Blending proceeds in a bin blender at 60 % fill volume and 12 rpm for 20 min, with the API first preblended 1:4 with microcrystalline cellulose through a 500 µm screen. Sodium stearyl fumarate is added last and mixed for 3 min to limit shear-induced agglomeration. Compression is performed on a 16-station rotary tablet press with 10 mm round biconvex tooling, precompression force 2.4 kN, main compression force 5.2–7.8 kN, target tablet hardness 45–65 N, and friability not more than 0.8 % after 100 rotations according to USP <1216>. Blend uniformity is verified under USP <905> with acceptance value ≤ 15.0, while dissolution is tested under USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid with Q ≥ 80 % at 30 min. The finished goods are round biconvex film-coated tablets packed in 60 cm³ HDPE bottles with a molecular sieve desiccant canister, and the assigned shelf life is supported by ICH Q1E bracketing after long-term data at 25 °C/60 % RH and intermediate data at 30 °C/65 % RH.

When Is High-Shear Wet Granulation Preferable to Direct Compression for a Fluorinated Pyrrolidine API?

High-shear wet granulation becomes the selected route when the fluorinated pyrrolidine hydrochloride dose exceeds 25 mg per unit, when direct compression formulations exceed 30 % w/w API and exhibit flow function coefficient below 4 on a ring shear tester, or when the particle size distribution of the API has fines below 10 µm exceeding 35 % by laser diffraction. A representative high-dose granulation uses API at 18.0–32.0 % w/w, microcrystalline cellulose 38.0–52.0 % w/w, crospovidone 4.0 % w/w, povidone K30 3.0 % w/w, and purified water or a 70:30 mixture of isopropanol and water as the granulating fluid. If the free base rather than the hydrochloride salt is used and the aqueous solubility at pH 6.8 falls below 0.05 mg/mL, the granulation fluid is switched to anhydrous ethanol or acetone to avoid dissolution-induced polymorph conversion; residual solvent limits are then controlled under ICH Q3C, with isopropanol not more than 5000 ppm and acetone not more than 5000 ppm in the final dried granule. The granulation is carried out in a 10 L high-shear granulator at impeller speed 300 rpm and chopper speed 1500 rpm, wet massing time 3–5 min, and target batch load 5.0 kg. If published granulation-endpoint data for the specific fluorinated pyrrolidine substitution pattern are limited, the wet massing endpoint is confirmed by torque rheometry rather than fixed time. The wet mass is dried in a fluid-bed dryer at inlet air temperature 60–65 °C until loss on drying reaches 1.5–2.5 % by USP <921>. Dried granules are milled through a 1.0 mm screen to a target D50 of 150–300 µm, then blended with extragranular crospovidone 2.0 % w/w and magnesium stearate 0.5 % w/w. The lubricated blend is compressed into 12 mm oval tablets with hardness 70–100 N or filled into size 0 hard capsules. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 4.5 acetate buffer, with Q ≥ 75 % at 45 min for film-coated tablets. Uniformity testing under USP <905> and disintegration testing under Ph Eur 2.9.1 are applied to the final coated tablets, and residual solvent testing under ICH Q3C plus USP <467> is executed on process validation batches. Terminal products are film-coated immediate-release tablets or granule-filled hard gelatin/HPMC capsules, depending on moisture barrier requirements.

Low-Dose Capsule Filling and Moisture Barrier Constraints for Fluorinated Pyrrolidine Hydrochloride

Powder-in-capsule operations for a fluorinated pyrrolidine hydrochloride are confined to filling rooms maintained at 18–25 °C and ≤40 % RH because the salt form can gain 2.0 % moisture within 60 min at 75 % RH; this moisture uptake shifts the powder flow profile and raises fill weight variability on dosator machines. The formulation is prepared with API at 0.5–10.0 mg per capsule, typically 3.0 mg in a 200 mg total fill, with 72.0 % w/w microcrystalline cellulose, 22.0 % w/w mannitol, 4.0 % w/w croscarmellose sodium, and 0.5 % w/w sodium stearyl fumarate. The blend is passed through a 600 µm mesh and mixed in a tote blender at 15 rpm for 25 min. Filling is performed on a tamping pin or dosator capsule machine at 70,000–90,000 capsules per hour, with fill weight control limits of ± 3.0 % and periodic checkweighing at 15-minute intervals. Hard HPMC capsules are selected instead of gelatin when the API is known to contain residual aldehydes or when the finished product is destined for tropical climate zones III/IV; hard gelatin capsules remain acceptable only if the fill mass water activity is below 0.45. In-process verification includes mass uniformity under USP <905>, dissolution under USP <711> in 0.01 N hydrochloric acid with Q ≥ 80 % at 30 min, and microbial enumeration under USP <61>/<62> with TAMC ≤ 10³ CFU/g and TYMC ≤ 10² CFU/g. Elemental impurities are controlled under ICH Q3D oral PDEs, and residual solvents under ICH Q3C. Terminal articles are size 3 or size 4 two-piece hard capsules, packed in cold-form aluminum-aluminum blisters when moisture protection exceeds that of PVC/PVDC, and the packaged configuration is subjected to container closure integrity testing under USP <1207> vacuum decay.

If Lyophilization Is Selected for a pH-Sensitive Fluorinated Pyrrolidine Injectable

Lyophilization is selected for a fluorinated pyrrolidine injectable when the API hydrochloride degrades more than 0.5 % total impurities in aqueous solution after 7 days at 25 °C and 75 % RH or when the solution shows visible precipitate at pH above 6.0. The bulk solution is compounded at a drug concentration of 5.0 mg/mL with 40 mg/mL mannitol as crystalline bulking agent and 20 mg/mL trehalose dihydrate as cryoprotectant, in Water for Injection q.s. to 5.0 mL per 10R vial. Sodium chloride is excluded from the formulation because chloride eutectic formation depresses collapse temperature during freezing; mannitol provides the crystalline structural matrix. The pH is adjusted to 4.8–5.2 with 0.1 N hydrochloric acid or 0.1 N sodium hydroxide under a nitrogen overlay because the fluorinated pyrrolidine moiety can undergo oxidative N-dealkylation if headspace oxygen exceeds 2.0 %. The solution is clarified through a 0.45 µm filter and sterilized by filtration through a 0.22 µm PVDF membrane in a Grade A/RABS environment. Filling uses peristaltic pumps with fill volume control ± 1.0 %. Freezing is conducted on lyophilizer shelves from ambient to -40 °C at 0.5 °C/min, followed by 4 h hold. Primary drying is executed at shelf temperature -25 °C and chamber pressure 0.2 mbar for 48 h; secondary drying at 25 °C and 0.1 mbar for 8 h. If published freeze-drying characterization data for the exact substitution pattern are limited, collapse temperature is confirmed by freeze-drying microscopy before cycle validation. The dried cake must show moisture below 1.0 % by Karl Fischer and reconstitution time not more than 90 s with 5.0 mL Water for Injection. Sterility is verified by USP <71>, bacterial endotoxins by USP <85>, particulate matter by USP <788> with ≥ 10 µm particles ≤ 6000 per container and ≥ 25 µm particles ≤ 600 per container, and package integrity by USP <1207> vacuum decay. Terminal presentations are lyophilized powder in 10R glass vials with rubber stoppers and flip-off seals, stored at 2–8 °C if stability data so require, and reconstituted immediately before intramuscular or intravenous administration as a 5.0 mL solution.

Granules for oral suspension serve as the dose-adjustable form for a fluorinated pyrrolidine hydrochloride when unit strengths below 2.0 mg are needed for pediatric or dysphagia patients. The API is dispersed at 0.25–5.0 mg per sachet, with total fill mass 1.0–2.0 g, in a vehicle consisting of 71.5 % w/w mannitol, 2.0 % w/w hydroxypropyl cellulose, 3.0 % w/w croscarmellose sodium, 0.3 % w/w xanthan gum, 0.2 % w/w sodium benzoate, 0.5 % w/w colloidal silicon dioxide, and 1.5 % w/w flavouring agent. A top-spray fluid-bed granulation is performed in a Glatt GPCG 3 with inlet air temperature 55–65 °C, spray rate 8–12 g/min, nozzle pressure 0.8 bar, and target granule D50 of 180 µm. The dried granule is blended with extragranular xanthan gum and silicon dioxide, then filled into aluminum/polyethylene stick packs with seal integrity tested by vacuum decay under USP <1207>. The stick pack film has a water vapour transmission rate not more than 0.05 g/m²/day at 38 °C/90 % RH, because moisture ingress above 0.5 % increases impurity formation during storage. The reconstituted suspension is expected to have pH of 4.2–5.0 to maintain the solubilized fraction of the fluorinated pyrrolidine hydrochloride; if the API exhibits bitterness, a 2.0 % w/w amino methacrylate copolymer coating may be applied to the granule to delay release in saliva. Quality controls include dissolution on the reconstituted suspension using USP <711> Apparatus 2 at 50 rpm in 500 mL of pH 4.5 acetate buffer with Q ≥ 80 % at 30 min, uniformity of mass under Ph Eur 2.9.5, residual solvents under ICH Q3C, and elemental impurities under ICH Q3D. Terminal products are single-dose granules for oral suspension, packed in 1.0 g or 2.0 g stick packs, reconstituted in 10 mL of water immediately before oral administration.

Terminal Sterilization Defers to Aseptic Filtration for Ready-to-Use Pyrrolidine Injection Solutions

Ready-to-use aqueous injection solutions of a fluorinated pyrrolidine hydrochloride are formulated at 1.0 mg/mL in 0.9 % w/v sodium chloride or 5 % w/v dextrose monohydrate, with pH adjusted to 4.8–5.2 using 0.1 N hydrochloric acid. The manufacturing sequence is aseptic processing rather than terminal steam sterilization unless forced degradation at 121 °C for 15 min demonstrates total impurities below 0.5 % area by HPLC; many fluorinated pyrrolidine derivatives exhibit thermal N-oxide formation or hydrolytic defluorination under autoclave conditions, so terminal sterilization is expressly excluded from the registered process when such data are absent. The drug solution is sparged with nitrogen to keep dissolved oxygen below 1.0 ppm before filtration through a 0.22 µm PVDF membrane. Filling is performed in an isolator under unidirectional airflow at ISO Class 5 according to ISO 14644-1, with fill volumes of 2.0 mL into 5 mL ampoules or 5.0 mL into 10 mL vials. Hold times between compounding and filtration are limited to 8 h at 2–8 °C to minimize pH drift and degradation. Aseptic process simulation runs are executed with tryptic soy broth under 21 CFR 211.113 and Ph Eur 2.6.1. Finished product testing includes sterility by USP <71>, bacterial endotoxins by USP <85> with a limit derived from the maximum human dose, particulate matter by USP <788>, subvisible particle counts by Ph Eur 2.9.19, pH by USP <791>, and related substances by an ICH Q3B-qualified HPLC method with unspecified impurities ≤ 0.10 % and total impurities ≤ 0.5 %. Amber glass containers are used if photostability under ICH Q1B shows N-oxide formation. Terminal presentations are ready-to-use solution for injection in 2 mL or 5 mL pre-filled syringes, 5 mL ampoules, or 10 mL single-dose vials, stored at 2–8 °C when photolytic or hydrolytic stability margins require refrigerated distribution.